Optimizing decision-making for initiating the treatment of hepatitis b virus infection in resource-limited settings: African consensus guidelines

Abstract
Optimization of hepatitis B virus (HBV) testing and linkage to treatment may help curtail the HBV disease burden in Africa. Therefore, a panel of 10 experts from Africa convened, reviewed the literature and developed 10 recommendations for optimizing the diagnosis and treatment initiation for HBV infection in Africa. In resource-constrained African settings, a single hepatitis B surface antigen assay may be considered as the primary test for HBV diagnosis. Pre-treatment assessments should include tests for complete blood count, liver/renal function, hepatitis B e-antigen (HBeAg), anti-HBe, HBV DNA, co-infection, and disease severity assessment. Non-invasive alternatives to liver biopsy include aspartate aminotransferase-to-platelet ratio index, fibrosis score-4, and transient elastography. Antiviral therapy should be initiated in HBV-infected, cirrhotic individuals with detectable HBV DNA, regardless of alanine transaminase levels or HBeAg status. This consensus document may be a useful guide to clinicians for optimizing the diagnosis and treatment initiation for HBV infection in Africa.

Keywords: hepatitis B virus, diagnosis, consensus, Africa

Abbreviations: WHO, world health organization; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; TE, transient elastography; AST, aspartate aminotransferase; ART, anti-retroviral therapy; APASL, association for the study of the liver, HCV, hepatitis C virus; ALT, alanine transaminases; PT, prothrombin time; ULN, upper limit of normal; GGT, gamma-glutamyl transpeptidase

Introduction
Epidemiology and burden of hepatitis b virus infection in Africa

According to the 2017 World Health Organization (WHO) global hepatitis report, the worldwide prevalence of hepatitis B virus (HBV) infection in 2015 in the general population was 3.5% (257million individuals). In this report, the WHO African region was reported to have the second highest prevalence, with about 60million individuals living with HBV infection (6.1%). In a recent modelling study, involving 120 countries conducted by the Polaris Observatory Collaborators, the modelled global prevalence of hepatitis B surface antigen (HBsAg) infection in the general population was found to be 3.9% in 2016, corresponding to about 291million individuals. In this study, the modelled prevalence of HBsAg infection in the Central, East, Southern, and West regions of sub-Saharan Africa in 2016 was found to be 10.1%, 5.1%, 8.5%, and 9.8%, respectively (corresponding to approximately 12.2, 22.2, 6.8, and 39.1million HBsAg-positive individuals, respectively). Recent epidemiological studies conducted in Central African Republic and Gabon (Central sub-Saharan Africa) have also revealed a high prevalence of HBV infection, especially in asymptomatic young adults, pregnant women, children and adolescents. Other recent systematic reviews and meta-analyses have indicated a high prevalence of HBV infection in Cameroon and Ghana (West sub-Saharan Africa) in the general population, blood donors, and pregnant women. One of the key reasons for the high prevalence of HBV infection in Africa is the very low neonatal vaccination rates. In Africa, all 3 doses of HBV vaccine
have been found to be administered to only 80% infants and the birth 
dose of the vaccine (within 24 hours after birth) to only 10% neonates 
in 2016. Within Africa, the 3-dose HBV vaccination was administered 
to 86%, 88%, 86%, and 66%; and the birth dose of the vaccine was 
administered to 0%, <1%, 3%, and 18% of infants in the Central, East, 
Southern and West sub-Saharan African regions, respectively. As a 
result of the low neonatal vaccination rates, the prevalence of HBsAg 
infection in children aged 5 years has been found to be the highest in 
the WHO African region in 2016 (3.4%), corresponding to over 1 million 
HBsAg-positive children aged 5 years. Adding to this public health 
concern in Africa is the increasing burden of HBV–HIV co-infections. 
In the WHO report, the sub-Saharan African region has been cited 
to have the highest number of HIV–HBV co-infected individuals 
(1.96 million; 71% of the global HIV-HBV co-infected population). Several 
regional studies have also reported a high prevalence of HIV– 
HBV co-infection.1,2

In addition to the high prevalence, chronic HBV infection is also 
associated with high morbidity in Africa. A multicenter, observational 
cohort study conducted in various African countries revealed HBV 
infection to be a leading cause of hepatocellular carcinoma (HCC) 
in the Cameroon, Ethiopia, Ghana, Ivory Coast, Nigeria, Sudan, 
Tanzania, and Uganda regions of Africa.3 In other regional cross-
sectional studies and series papers, HIV–HBV co-infection has been 
cited to be an important risk factor for aggressive liver disease, 
acute liver failure, HCC at a younger age, and significant fibrosis/ 
cirrhosis.4,5 A statistical model based on a systematic review of data 
from 50 countries and data from GLOBOCAN 2012 revealed that 
about 50% of liver cancer cases in sub-Saharan Africa are caused due 
to HBV infection.6

The mortality from HBV infection has also been found to be 
high, both globally and in Africa. In the 2017 WHO global hepatitis 
report, about 1.34 million global deaths were attributed to viral 
hepatitis in 2015. Of these deaths, about 66% were noted to be the 
result of complications due to chronic HBV infection. The African 
region stands third with respect to mortality from viral hepatitis, with 
about 136,000 deaths recorded in 2015.7 Furthermore, augmenting 
this burden is the clinical observation that the mortality from HBV-
associated HCC occurs at a younger age (median: 38.9 years) in sub-
Saharan Africa, thus resulting in more years of life lost and greater 
economic loss in this region.8

One of the core interventions that can help curtail the morbidity 
and mortality from HBV infection is the scale-up of HBV testing and 
timely linkage to treatment and care.9,10 However, there are several 
unmet needs in the diagnosis and initiation of treatment for HBV 
infection in Africa that hinder the effective implementation of this 
intervention.

Key unmet needs in the diagnosis and initiation of treatment of HBV infection in Africa

Hepatitis B virus infection remains largely underdiagnosed in 
Africa. A considerably low percentage of HBV-infected individuals 
in Africa are aware of their diagnosis.1 Identification of individuals 
infected with HBV and assessing the need to initiate treatment 
has been found to be difficult in Africa, due to the asymptomatic 
nature of chronic HBV infection and the economic and accessibility 
constraints associated with diagnostic testing.2,3 Although liver biopsy 
is the standard test for the assessment of fibrosis, its use in routine 
clinical settings in sub-Saharan Africa is limited due to its cost and 
invasive nature.1,3 The use of transient elastography (TE), a non-
 invasive method for diagnosing advanced fibrosis, is also limited 
in this region due to cost and accessibility issues and the need for 
trained operators.4,5,6 The aspartate aminotransferase (AST)-to-
platelet ratio index (APRI) score is a WHO-preferred, cost-effective, 
non-invasive testing method that can help identify individuals 
with cirrhosis; however, its use in Africa has been reported to be 
minimal.7,8 Nucleic acid testing (NAT) or testing for HBV DNA, 
which is essential to detect individuals with high viremia, is costly 
and not easily accessible in Africa. Therefore, there is a clear unmet 
need for affordable, readily accessible, WHO-prequalified, point-of- 
care HBV testing services in low- and middle-income countries and 
resource-limited settings, such as Africa.9

Owing to the aforementioned barriers, HBV screening/testing rates 
have been found to be suboptimal in various regions in Africa.10,11 In 
a recent medical chart review of 3579 charts of patients initiating 
anti-retroviral therapy (ART), from large urban HIV treatment 
centers (n = 12) across sub-Saharan Africa, systematic screening for 
HBV infection before initiating ART was found to be poor: less than 
a quarter of the patients were tested for the presence of HBV 
infection.12 Suboptimal screening has been also reported in other 
surveys conducted in low- and middle-income countries, including 
those from the African region.13 A clear need for targeted HBV 
screening of healthcare workers; medical waste handlers; commercial 
sex workers; people living with HIV; close contacts of HBV-infected 
individuals; hemodialysis patients; pregnant women; and individuals 
with established cirrhosis or decompensated liver disease has been 
highlighted in several regional studies.14,15

In addition to these screening and diagnostic gaps, it has also 
been noted that, due to easy access to ART, the HIV-HBV co-infected 
individuals in most African regions are administered life-saving ART 
regimens, most of which contain lamivudine, which has been found to 
cause the development of HBV-resistant mutants. This finding clearly 
highlights the unmet need for HBV screening prior to initiation of 
ART in this patient population.16,17

Other regional studies and surveys have highlighted the following 
additional major challenges to the scale-up of testing and timely 
linkage to treatment and care in Africa: (1) lack of national guidelines 
and strategic frameworks for HBV testing and screening; (2) lack of 
simplified diagnostic algorithms; and (3) the lack of clear referral 
pathways.14,18-20

Methodology of consensus development

In view of the high prevalence and burden of HBV, and the cited 
unmet needs in the diagnosis and initiation of treatment for HBV 
infection in Africa, a panel of 10 experts from 6 African countries 
convened to develop a consensus document to optimize decision-
making and initiation of treatment of HBV infection in Africa. The 
expert panel reviewed the latest recommendations for the management 
of HBV infection from the Asian Pacific Association for the Study 
of the Liver (APASL), the European Association for the Study of 
the Liver (EASL), and the American Association for the Study of 
Liver Diseases (AASLD), and proposed recommendations for the 
diagnosis, pre-treatment assessment, and indications of therapy for 
HBV infection—along with recommendations for the management 
of special patient populations, such as those with cirrhosis, and co-
infection in Africa. Algorithms were also developed to guide decision-
making for the initiation of treatment in HBeAg-positive and HBeAg-
negative treatment naïve patients.

This guidance document has been developed by the consensus of 
the expert panel based on: (1) formal review and analysis of relevant 
Citation: Gane EJ, Charlton MR, Oryekwere CA, et al. Optimizing decision-making for initiating the treatment of hepatitis b virus infection in resource-limited settings: African consensus guidelines. Gastroenterol Hepatol Open Access. 2019;10(4):202–211. DOI: 10.15406/ghoa.2019.10.00383
published literature, including various chronic HBV management guidelines; and (2) the panels’ experience in the management of HBV infection. The Grading of Recommendations Assessment, Development, and Evaluation system was not used for rating of the recommendations by the panel.

**Diagnostic criteria for chronic HBV infection**

According to the APASL and AASLD guidelines, serological assays for HBsAg and hepatitis B surface antibodies (anti-HBs) should be conducted for the diagnosis of chronic HBV infection. Alternatively, testing for total hepatitis B core antibody (total anti-HBc) may also be done for the detection of HBV infection; however, additional HBsAg and anti-HBs testing may be required in anti-HBc-positive individuals to differentiate infection from immunity. Furthermore, the AASLD guidelines do not recommend the routine use of anti-HBc testing, and recommend it as a useful test primarily for the detection of HBV infection: (1) in patients who have HIV infection, or are about to initiate hepatitis C virus (HCV), anticancer or other immunosuppressive therapies or renal dialysis; and (2) in donated blood (or organs). Considering the high prevalence of HBV infection in African settings, the expert panel recommended the use of a single serological assay for the detection of HBsAg for the diagnosis of chronic HBV infection (Table 1).  

**Pre-treatment assessment of individuals with HBV infection**

The initial assessment of all HBsAg-positive individuals should include: (1) detailed history-taking, including details of alcohol consumption, comorbidities, and risk factors; (2) evaluation of family history for cirrhosis or liver cancer; and (3) a thorough physical examination for identifying the presence of cirrhosis or decompensated liver disease. Other pre-treatment assessments should include the following (Table 2).

### Table 1  Recommendation for diagnosis of HBV infection

| Recommendation number | Recommendation |
|-----------------------|----------------|
| I                     | An assay for HBsAg is the primary test for the diagnosis of chronic HBV infection. |

**Table 2  Recommendations for pre-treatment assessments in individuals with chronic HBV infection**

| Recommendation number | Recommendation |
|-----------------------|----------------|
| II                    | The initial evaluation of an individual with HBV infection should include detailed history-taking, family history assessment, thorough physical examination, assessment of complete blood count, and biochemical tests to assess liver/renal function. Serological markers (HBeAg, anti-HBe, and HBV DNA) to assess the phase of infection and the extent of viral replication; and coinfection markers to rule out HAV, HCV, HDV, and HIV should be conducted as a part of the pre-treatment assessment. Non-invasive markers such as APRI, FIB-4, or TE may be used to assess the extent of fibrosis. The cut-off for APRI for the detection of significant fibrosis is ≥1.5, and that for cirrhosis is ≥2.0. A FIB-4 threshold >3.25 is indicative of advanced fibrosis and a threshold <1.45 is suggestive of minimal fibrosis. A TE measurement >9 kPa, and >12 kPa is suggestive of significant fibrosis and cirrhosis, respectively. In Africa, TE may be a reasonable alternative to liver biopsy for the assessment of fibrosis in HBV-infected patients. Liver biopsy may be reserved for patients with a high viral load and high-normal or minimally raised ALT levels without clinical evidence of cirrhosis. If TE is not available or accessible, APRI or FIB-4 may be used as effective alternatives for the detection of liver fibrosis and cirrhosis. |
| III                   | Complete blood count |
| IV                    | Liver function tests: Assessment of liver function should include tests for aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), bilirubin, albumin, and prothrombin time (PT). The upper limit of normal (ULN) for ALT for guiding the treatment of chronic HBV infection in African patients may be considered as 35 U/L in males, and 25 U/L in females, in line with American guideline recommendations. Derangement of liver enzymes has been noted in both HBV-infected and HBV-HIV co-infected individuals in studies conducted in various African regions. Elevated levels of aminotransferases have been found to significantly correlate with viral load in HBV-infected individuals. However, the use of liver enzyme levels as a single biomarker for assessing liver damage and/or disease progression is not encouraged. Assessment of liver enzymes should be done alongside other virological markers to assess the progression of HBV infection. |

**Renal function test: Includes test for serum creatinine**

**Virological tests:** The virological markers that should be tested include HBeAg, antibodies to HBeAg (anti-HBe), and HBV DNA. The virological markers, HBeAg and anti-HBe have been found to be suggestive of active viral replication in HBV-infected individuals in regional studies. In these studies, the prevalence of HBeAg was found to be higher among HBV-infected individuals aged 0–20years with a decrease in prevalence with increasing age; on the contrary, an increase in anti-HBe was noted with advancing age. Furthermore, HBeAg-positivity was found to be associated with a significantly...
higher risk for cirrhosis (11.2-fold) and HCC (6.7-fold), after adjusting for age, gender, and socioeconomic status in a prospective case-control study conducted in West Africa (asymptomatic HBV carriers, n=60; cirrhotic patients, n=53, and HCC cases, n=129). In the same study, a strong and significant correlation was noted between HBV DNA levels and cirrhosis and HCC, independent of the HBeAg status; high-level viremia (>20000 IU/mL) was associated with a 17.3-fold and 38.8-fold increased risk of cirrhosis and HCC, respectively. Therefore, HBV DNA may be an important marker of viral replication, and may help guide decision-making regarding the initiation and monitoring of antiviral treatment in HBV-infected individuals.22,23,25,26

Assessment for markers of co-infection: Tests should be conducted for the detection of antibodies to hepatitis A, D, and C virus (anti-HAV, anti-HDV, and anti-HCV, respectively), and HIV, to exclude co-infection, or initiate appropriate treatment.22,23,25 Regional variations in the endemicity of HDV virus has been reported in recent studies, and hence, may be considered during assessment for markers of co-infection. In a systematic review and meta-analysis of 30 studies to assess the prevalence of HDV among HBsAg-positive individuals in sub-Saharan Africa, the pooled seroprevalence of HDV in Central Africa was noted to be 25.64% in the general population and 37.77% in individuals with liver disease. The corresponding rates in West Africa were noted to be 7.33% and 9.57%, respectively. In East and Southern Africa, the seroprevalence of HDV in the general population was noted to be much low at 0.05%. However, overall, a significantly higher chance of detection of anti-HDV was noted among HBsAg-positive patients with liver fibrosis or HCC compared to asymptomatic controls.26 A high prevalence of HBV and HDV co-infection in the Central African Republic has also been cited in other regional studies. Therefore, regional variations and the presence of concomitant liver disease may be considered while assessing for anti-HDV in HBV-infected individuals.

Histological evaluation of the extent of fibrosis and liver disease should also be a part of the pre-treatment assessment in HBV-infected individuals. Liver biopsy is considered as the reference standard for assessing the extent of fibrosis. However, its use may be subject to sampling errors, interpretational variability, and safety concerns owing to its invasive nature.22,23 Therefore, a liver biopsy may be reserved for patients with a high viral load and high-normal or minimally raised ALT levels without clinical evidence of cirrhosis.22,25 An Ishak fibrosis stage ≥3 or METAVIR fibrosis score F ≥2 is indicative of significant fibrosis on liver biopsy.22,23 Furthermore, cirrhosis on liver biopsy refers to an Ishak fibrosis stages 5 and 6 or METAVIR fibrosis score of F4.22,23,34

The expert panel recommended the use of non-invasive tests such as APRI, fibrosis score 4 (FIB-4), or TE for the accurate assessment of the extent of hepatic fibrosis to guide treatment selection in HBV-infected individuals.22,24,25 The APRI is a simple and inexpensive test that can be easily performed in an outpatient setting. The cut-off for APRI for the detection of significant fibrosis is ≥1.5, and that for cirrhosis is ≥2.0.21 These thresholds have been successfully used in regional studies to assess the extent of fibrosis and cirrhosis. In a study conducted in Tanzania, HIV-HBV co-infected individuals (n=227) were found to have a significantly higher prevalence of APRI scores, suggestive of fibrosis and cirrhosis, than HIV-monoinfected individuals (n=2870). Furthermore, regression of APRI was noted in HIV-HBV co-infected individuals treated with appropriate ART.38 In another study conducted in Zambia that used the aforementioned APRI thresholds for the assessment of liver fibrosis and cirrhosis, it was noted that HBsAg-positive individuals were more likely to have significant liver fibrosis than HBsAg-negative individuals.39 The FIB-4 score is another non-invasive index that has been used to assess the extent of fibrosis in HBV-infected individuals. Cut-off FIB-4 scores of 1.45 and 3.25 have been found to identify the extent of HBV-related fibrosis.37 The expert panel recommended an FIB-4 threshold ≥3.25 to be indicative of advanced fibrosis and a threshold <1.45 to be suggestive of minimal fibrosis. These thresholds have been successfully used in two separate studies conducted in South Africa and North-Western Tanzania.38,39

The use of APRI and FIB-4 may not be ideal for the assessment of HBV-related fibrosis in patients with HBV infection with persistently normal ALT levels.40 Liver stiffness measurement using TE or Fibroscan may be more useful in these patients.22,40 The expert panel recommended a liver stiffness measurement >9 kPa, and >12 kPa to be suggestive of significant fibrosis and cirrhosis, respectively in HBV-infected individuals.22 Closer thresholds have been used in studies conducted in various regions in Africa for the evaluation of fibrosis in HBV-infected and HIV-HBV co-infected individuals.41-44 In low-income settings such as Africa, TE may a reasonable alternative to liver biopsy for the assessment of fibrosis in HBV-infected patients.41 Furthermore, if TE is not available or accessible, APRI or FIB-4 may also be used as effective alternatives for the detection of liver fibrosis and cirrhosis, in resource-limited settings such as Africa (Table 2).24,25

In Africa, HBV infection is one of the leading causes of HCC.1,12,45 Contrary to the observation that HCC increases progressively with advancing age, the mean age of patients with HCC in Africa is considerably younger. Furthermore, the risk of HCC development, even in the absence of cirrhosis is high in HBV-infected individuals in endemic settings such as Africa.46 According to the latest European guidelines for the management of HCC, HCC surveillance should be offered to: (1) cirrhotic patients, Child-Pugh stage A and B; (2) cirrhotic patients, Child-Pugh stage C awaiting liver transplantation; (3) non-cirrhotic HBV-infected patients at intermediate or high HCC risk; and (4) non-cirrhotic F3 patients, regardless of etiology, based on individual risk assessment.46 However, it may be difficult to implement HCC surveillance in all the stated risk groups in Africa due to cost constraints. Furthermore, this scenario may be even more complicated by poor access to curative therapies such as resection in individuals detected with HCC.

In addition to these pre-treatment assessments, the AASLD guidelines recommend HBV genotype testing in selected patients, as some specific genotypes have been found to be associated with an increased risk of liver disease progression, and response to pegylated interferon alpha (PegIFN-α) therapy.22 An association between the HBV genotype and the risk of HCC has also been reported in the African region. Of the various HBV genotypes, type A1 is more prevalent in sub-Saharan Africa, type A3 is prevalent in West Africa, type D is prevalent in North Africa, and type E is prevalent in West and Central Africa. Of these genotypes, A1 has been found to be associated with a high rate of HCC, especially in young males, often in those without cirrhosis.47,48 Therefore, genotype testing may be useful in selected group of HBV-infected individuals. Furthermore, the EASL guidelines recommend HBsAg quantification in HBsAg-negative HBV-infected patients and in patients in whom IFN-α treatment is planned.22,23 However, the expert panel did not recommend these additional tests, considering the resource-limited settings in Africa.
Indications for initiation of therapy in patients with HBV infection

The indications for initiation of antiviral therapy in individuals with chronic HBV infection should be based on a combination of criteria: (1) serum HBV DNA levels; (2) serum ALT levels; and (3) severity of liver disease (assessed by clinical evaluation, non-invasive markers or liver biopsy). Indication for treatment should also consider other criteria such as age, family history of HCC or cirrhosis, and extrahepatic manifestations. The thresholds or the upper limit of normal (ULN) for ALT may be considered as 35U/L for males and 25U/L for females.

The expert panel systematically compared the APASL, AASLD, and EASL guidelines and analyzed the recommendations from these guidelines for the initiation of therapy in compensated and decompensated cirrhotic individuals, and in non-cirrhotic HBeAg-positive and -negative individuals, based on the above criteria. After reviewing the three guideline recommendations, the expert panel recommended that all HBV-infected, cirrhotic (compensated or decompensated) individuals with detectable serum HBV DNA levels should be started on antiviral therapy, regardless of the ALT levels or HBeAg status (Table 3). Initiation of antiviral therapy has been found to effectively control viral replication and improve the biochemical and clinical parameters in patients with compensated or decompensated HBV cirrhosis. Continuous treatment with antiviral therapy in HBV patients with advanced fibrosis or confirmed cirrhosis has been noted to prevent the clinical progression of the disease by significantly reducing the incidence of hepatic decompensation and the risk of HCC. Furthermore, regression of fibrosis and cirrhosis have been reported with long-term suppression of viral replication with antiviral therapy in HBV patients with advanced fibrosis. Considering the high morbidity and mortality from HBV infection, an aggressive approach involving the early detection and initiation of antiviral therapy may help reduce the incidence and mortality from HBV-associated HCC in resource-limited settings such as Africa.

Table 3 Recommendation for indications for therapy initiation in HBV-infected, cirrhotic individuals

| Recommendation number | Recommendation |
|-----------------------|----------------|
| V                    | All HBV-infected, cirrhotic (compensated or decompensated) individuals with detectable serum HBV DNA levels should be started on antiviral therapy, irrespective of ALT levels or HBeAg status. |

The expert panel also developed two simple algorithms for easy guidance on the initiation of antiviral therapy in non-cirrhotic HBeAg-positive and -negative treatment-naive individuals (Figures 1 & 2). The usage of these algorithms has been described in detail under recommendations 6 and 7 (Tables 4 & 5).

Table 4 Recommendation for guidance on therapy initiation in non-cirrhotic, HBeAg-positive, treatment-naive, HBV-infected individuals (Figure 1)

| Recommendation number | Recommendation |
|-----------------------|----------------|
| VI                   | The initial assessment to guide treatment initiation in this group of patients should be based on HBV DNA levels. If the HBV DNA is >20,000IU/mL, further assessment should be based on ALT levels. If the ALT level is >ULN, appropriate antiviral treatment should be initiated. In individuals with ALT <ULN, antiviral treatment should be initiated in the presence of any one of the following criteria: |
|                       | Age >30 years |
|                       | Presence of at least moderate fibrosis |
|                       | Family history of cirrhosis or HCC |
|                       | Presence of extrahepatic manifestations |
|                       | If the HBV DNA is between 2000 and 20,000IU/mL, antiviral therapy can be initiated in the presence of any one of the following criteria, regardless of the ALT levels: |
|                       | Age >30 years |
|                       | Presence of at least moderate fibrosis |
|                       | Family history of cirrhosis or HCC |
|                       | Presence of extrahepatic manifestations |
|                       | Patients with detectable serum HBV DNA levels <2000IU/mL can be treated with antiviral therapy in the presence of extrahepatic manifestations or a family history of cirrhosis or HCC, regardless of the ALT levels. |

HBV: Hepatitis B virus; HBeAg: Hepatitis B e-antigen; DNA: Deoxyribonucleic acid; ALT: Alanine aminotransferase; ULN: Upper limit of normal; HCC: Hepatocellular carcinoma

Citation: Gane EJ, Charlton MR, Oryekwere CA, et al. Optimizing decision-making for initiating the treatment of hepatitis B virus infection in resource-limited settings: African consensus guidelines. Gastroenterol Hepatol Open Access. 2019;10(4):202–211. DOI: 10.15406/ghoa.2019.10.00383
Optimizing decision-making for initiating the treatment of hepatitis B virus infection in resource-limited settings: African consensus guidelines

Monitoring of HBV-infected patients, currently not being treated

Periodic assessment of serum ALT, HBV DNA levels and severity of liver fibrosis by non-invasive tests, should be conducted in all HBV-infected patients, not suitable for initiation of antiviral therapy: (1) every 3–6 months in HBeAg-positive HBV-infected patients <30 years of age; (2) every 6–12 months in HBeAg-negative HBV-infected patients with HBV DNA <2000 IU/mL; and (3) every 3 months for the first one year and every 6 months thereafter in HBeAg-negative HBV-infected patients with HBV DNA ≥2000 IU/mL.

Guidance for stopping of antiviral therapy in HBV-infected patients

Antiviral therapy may not be able to achieve complete HBV eradication or HBsAg loss in HBV-infected patients.23,25 Therefore, long-term antiviral treatment should be given in most chronically HBV-infected patients. Stopping of antiviral therapy may be considered after HBsAg loss, with or without seroconversion to anti-HBs. In HBV-infected, HBeAg-positive, non-cirrhotic patients, who have completed at least 12 months of consolidation therapy, discontinuation of antiviral therapy may be considered if stable HBeAg seroconversion and undetectable HBV DNA have been noted. In HBV-infected, HBeAg-negative, non-cirrhotic patients, who have achieved ≥3 years of virologic suppression, stopping of antiviral therapy may be considered.21 Literature suggests that on-treatment virologic suppression for >24 months may be associated with greater chances of virologic remission after discontinuation of treatment in HBV-infected, HBeAg-negative patients.

Indications for therapy in HBV-infected individuals with co-infection

HIV Co-infection

All HIV-positive patients with HBV co-infection should be administered ART, irrespective of the CD4 cell count; tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF)-containing regimens should be used (Table 6). Both TDF- and TAF-containing regimens have been reported to be effective in causing virological suppression to undetectable levels in separate clinical studies and meta-analyses.

Table 5 Recommendation for guidance on therapy initiation in non-cirrhotic, HBeAg-negative, treatment-naïve, HBV-infected individuals (Figure 2)

| Recommendation number | Recommendation |
|-----------------------|----------------|
| 1. | The initial assessment to guide treatment initiation in this group of patients should be based on HBV DNA levels. |
| 2. | If the HBV DNA is >2000 IU/mL, further assessment should be based on the ALT levels. If the ALT level is > ULN, antiviral treatment should be initiated. In individuals with ALT level <ULN, antiviral treatment should be initiated in the presence of any one of the following criteria: |
| VII | Age |
| o | >30 years |
| o | Presence of at least moderate fibrosis |
| o | Family history of cirrhosis or HCC |
| o | Presence of extrahepatic manifestations |
| o | Patients with detectable serum HBV DNA levels <2000 IU/mL can be treated with antiviral therapy in the presence of extrahepatic manifestations or a family history of cirrhosis or HCC, regardless of the ALT levels. |

Table 6 Recommendations for indications for therapy in HBV-infected patients with co-infections

| Recommendation number | Recommendation |
|-----------------------|----------------|
| VIII | All HIV-positive patients with HBV co-infection should be administered ART, irrespective of the CD4 cell count. |
| IX | All HCV RNA-positive patients with HBV co-infection should be considered for HCV DAA therapy. All HBV-HCV co-infected patients who fulfill the standard treatment criteria for HCV listed in the proposed algorithms (Figures 1-2) should receive HBV antiviral treatment. |
| X | Pegylated interferon alpha for at least 48 weeks is the current treatment of choice for HDV-HBV co-infected patients. |

HCV Co-Infection

Co-infection with HBV and HCV accelerates the progression of liver disease and increases the risk of HCC.26-28 All HCV RNA-positive patients with HBV co-infection should be considered for HCV direct-acting antiviral (DAA) therapy (Table 6). Treatment of HCV infection with DAAs may cause reactivation of HBV.29,30 Therefore, all HBV-HCV co-infected patients who fulfill the standard treatment criteria for HBV listed in the proposed algorithms (Figures 1 & 2) should receive HBV antiviral treatment. Other patients may be monitored by regular assessment of HBV DNA and ALT during HCV DAA therapy. Antiviral therapy for HBV infection may be initiated in these patients, if they develop HBV reactivation (defined as an increase in HBV DNA by at least 1 log plus elevation in ALT >ULN). Due to...
the resource-limited settings in Africa, if HBV DNA monitoring is not possible during HCV anti-viral therapy, anti-HBV therapy may be initiated in patients with a risk of HBV reactivation.

**Figure 1** Algorithm to guide initiation of antiviral therapy in non-cirrhotic, HBeAg-positive, treatment-naïve, HBV-infected individuals.

**Figure 2** Algorithm to guide initiation of antiviral therapy in non-cirrhotic, HBeAg-negative, treatment-naïve, HBV-infected individuals.
HDV Co-infection

Pegylated interferon alpha for at least 48 weeks is the current treatment of choice for HDV-HBV co-infected patients (Table 6). Treatment with PegIFN-α has been found to be associated with an improvement in biochemical and virological parameters in chronic HDV infection.80

In HBV-HDV co-infected patients with active HBV replication, appropriate antiviral therapy should be initiated for the treatment of HBV infection.

Summary

The high prevalence of, and increased morbidity and mortality from, HBV infection in Africa necessitates an urgent need for the scale-up of diagnosis of HBV infection and timely linkage to treatment and care. Development of national HBV diagnostic guidelines and simple diagnostic algorithms will help provide guidance on the screening and diagnosis and parameters to be considered for decision-making on the initiation of treatment for HBV infection in Africa. The current African consensus guidelines provide comprehensive recommendations on the diagnosis, pre-treatment assessments, and indications for initiation of therapy in HBV-infected individuals, including for those with co-infection. Implementation of these recommendations in real-world clinical practice will help to a large extent in the scaling up of diagnosis and increasing the rates of treatment for HBV infection in Africa.

Acknowledgements

We would like to thank Mylan Pharmaceuticals Ltd for financial support in execution of this project. We would also like to thank BioQuest Solutions Ltd for providing writing assistance.

Conflicts of interests

Author Edward John Gane: Member of Clinical Advisory Board for Gilead Sciences, AbbVie, Janssen, Arrowhead, Merck, VIR Biotechnology, and Assembly Bio. Member of Speakers’ Bureau for Gilead Sciences, AbbVie, Mylan Pharmaceuticals

Author Michael Charlton: Consulting and research support for Gilead Sciences, Merck, AbbVie, Novartis and Only consulting support for Mylan

Author Nadia Jacqueline Mandeng: Transport and accommodation in the consensus building meetings was provided by Mylan

Author Ravishankar AC: Employee of Mylan Pharmaceuticals Private Limited

Author Sanjay Hadigal: Employee of Mylan Pharmaceuticals Private Limited

Funding Information

The project is supported by Mylan Pharmaceuticals Ltd.

References

1. World Health Organization. Global Hepatitis Report 2017. Geneva: World Health Organization; 2017.
2. Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383–403.
3. Komnas NP, Ghosh S, Abdou-Chekarau M, et al. Hepatitis B and hepatitis D virus infections in the Central African Republic, twenty-five years after a fulminant hepatitis outbreak, indicate continuing spread in asymptomatic young adults. PLoS Negl Trop Dis. 2018;12(4):e0006377.
4. François-Souquière S, Makuwa M, Bisvigou U, et al. Epidemiological and molecular features of hepatitis B and hepatitis delta virus transmission in a remote rural community in central Africa. Infect Genet Evol. 2016;39:12–21.
5. Bigna JJ, Amougou MA, Asangbe SL, et al. Serore prevalence of hepatitis B virus infection in Cameroon: a systematic review and meta-analysis. BMJ Open. 2017;7(6):e015298.
6. Ofori–Asenso R, Ayegyam AA. Hepatitis B in Ghana: a systematic review & meta-analysis of prevalence studies (1995–2015). BMC Infectious Diseases. 2016;16:130.
7. Baseke J, Musenero M, Mayanja-Kizza H. Prevalence of hepatitis B and C and relationship to liver damage in HIV infected patients attending Joint Clinical Research Centre Clinic (JCRC), Kampala, Uganda. Afr Health Sci. 2015;15(2):322–327.
8. Ayegyam AA, Ofori–Asenso R. Prevalence of HIV and hepatitis B coinfection in Ghana: a systematic review and meta-analysis. AIDS Res Ther. 2016;13.23.
9. Yang JD, Mohamed EA, Aziz AO, et al. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. Lancet Gastroenterol Hepatol. 2017;2(2):103–111.
10. Hawkins C, Christian B, Fabian E, et al. Brief report: HIV/HBV coinfection is a significant risk factor for liver fibrosis in Tanzanian HIV–Infected adults. J Acquir Immune Defic Syndr. 2017;76(3):298–302.
11. Spearman CW, Athene M, Ally R, et al. Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets. Lancet Gastroenterol Hepatol. 2017;2(12):900–909.
12. Maucoţ-Bouch D, de Martel C, Franceschi S, et al. Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. Int J Cancer. 2018;142(12):2471–2477.
13. World Health Organization. WHO highlight the true burden of hepatitis B virus (HBV) prevalence in Africa with the pioneering work of the MRC Unit the Gambia. Geneva: World Health Organization; 2018.
14. Ishizaki A, Bouscaillou J, Luhmann N, et al. Survey of programmatic experiences and challenges in delivery of hepatitis B and C testing in low- and middle-income countries. BMC Infectious Diseases. 2017;17(Suppl 1):696.
15. Reipold EI, Trianni A, Krakower D, et al. Values, preferences and current hepatitis B and C testing practices in low- and middle-income countries: results of a survey of end users and implementers. BMC Infectious Diseases. 2017;17(Suppl 1):702.
16. Easterbrook P, Johnson C, Figueroa C, et al. HIV and Hepatitis Testing: Global Progress, Challenges, and Future Directions. AIDS Rev. 2016;18(1):3–14.
17. Lemoine M, Nayagam S, Thursz M. Viral hepatitis in resource–limited countries and access to antiviral therapies: Current and future challenges. Future Virol. 2013;8(4):371–380.
18. Coffie PA, Egger M, Vinikoor MJ, et al. Trends in hepatitis B virus testing practices and management in HIV clinics across sub-Saharan Africa. BMC Infectious Diseases. 2017;17(Suppl 1):706.
19. Shiferaw F, Letebo M, Bane A. Chronic viral hepatitis: policy, regulation, and strategies for its control and elimination in Ethiopia. BMC Public Health. 2016;16(1):769.
20. Di Bisceglie AM, Maskew M, Schulze D, et al. HIV–HBV co–infection among South African patients receiving antiretroviral therapy. *Antivir Ther*. 2010;15(3 Pt 3):499–503.

21. Kouvanfack C, Aghokhe AF, Mondain AM, et al. Lamivudine–resistant HBV infection in HIV–positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon. *Antivir Ther*. 2012;17(2):321–326.

22. Sarin SK, Kumar M, Lau GK, et al. Asian–Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update. *Hepatol Int*. 2016;10(1):1–98.

23. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology*. 2018;67(4):1560–1599.

24. World Health Organization. WHO guidelines on hepatitis B and C testing. Geneva: World Health Organization; 2017.

25. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. *J Hepatol*. 2017;67(2):370–398.

26. Tufon KA, Merki JD, Anong DN, et al. Genetic diversity, virasemia and aminotransferases levels in chronic infected hepatitis B patients from Cameroon. *BMC Research Notes*. 2016;9:117.

27. Davidson UN, Chidiebele NI, Josephine EI, et al. The prevalence liver function and immunologic status of children with HIV and hepatitis B virus coinfection in Enugu, Nigeria. *Afr J Infect Dis*. 2016;10(2):61–68.

28. Forbi JC, Iperpolu OY, Zungwe T, et al. Prevalence of Hepatitis B e Antigen in chronic HBV carriers in North–central Nigeria. *J Health Popul Nutr*. 2012;30(4):377–382.

29. Rufai T, Mutochel M, Kwartaeg K, et al. The prevalence of Hepatitis B virus E antigen among Ghanaian blood donors. *Pan Afr Med J*. 2014;17:53.

30. Mandy ME, Welzel T, Lesi OA, et al. Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in the Gambia, West Africa. *J Viral Hepat*. 2010;17(2):115–122.

31. Stockdale AJ, Chaponda M, Beloukas A, et al. Prevalence of Hepatitis D virus infection in sub–Saharan Africa: A systematic review and meta–analysis. *Lancet Glob Health*. 2017;5(10):e992–e1003.

32. Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. *J Hepatol*. 2009;50(1):1–3.

33. Sun Y, Zhou J, Wang L, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment. *Hepatology*. 2017;65(5):1438–1450.

34. Bedossa P, Poyrand T. An Algorithm for the grading of activity in chronic Hepatitis C. The METAIRV Cooperative Study Group. *Hepatology*. 1996;24(2):289–293.

35. Ramírez–Menà A, Glass TR, Winter A, et al. Prevalence and outcomes of Hepatitis B co–infection and associated liver disease among antiretroviral therapy– naive individuals in a rural Tanzanian human immunodeficiency virus cohort. *Open Forum Infect Dis*. 2016;3(3):ofw162.

36. Wandelger G, Mulenga L, Vinikoor MJ, et al. Liver fibrosis in treatment–naive–infected and HIV/HBV–coinfected patients: Zambia and Switzerland compared. *Int J Infect Dis*. 2016;51:97–102.

37. Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis–4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: A systemic review and meta–analysis. *Hepatology*. 2015;61(1):292–302.

38. Ivey P, MacLeod W, Mkunula N, et al. Low Prevalence of liver disease but regional differences in HBV treatment characteristics mark HIV/ HBV co–infection in a South African HIV clinical trial. *PLoS One*. 2013;8(12):e74900.

39. Kilonzo SB, Gunda DW, Kashasha F, Mpondo BC. Liver fibrosis and Hepatitis B coinfection among ART Naïve HIV–infected patients at a tertiary level hospital in Northwestern Tanzania: A cross–sectional study. *J Trop Med*. 2017;5629130:1–6.

40. Tan Y–W, Zhou X–B, Ye Y, et al. Diagnostic value of FIB–4, aspartate aminotransferase–to–platelet ratio index and liver stiffness measurement in hepatitis B virus–infected patients with persistently normal alanine aminotransferase. *World J Gastroenterol*. 2017;23(31):5746–5754.

41. Aberra H, Desalegn H, Berhe N, et al. Early experiences from one of the first treatment programs for chronic hepatitis B in sub–Saharan Africa. *BMC Infections Diseases*. 2017;17(1):438.

42. Vinikoor MJ, Sinkala E, Chilenga R, et al. Impact of antiretroviral therapy on liver fibrosis among human immunodeficiency virus–infected adults with and without HBV Coinfection in Zambia. *Clin Infect Dis*. 2017;64(10):1343–1349.

43. Mbaye PS, Sarr A, Sire JM, et al. Liver Stiffness measurement and biochemical markers in Senegalese chronic Hepatitis B Patients with normal ALT and high viral load. *PLoS One*. 2011;6(7):e22291.

44. Hawkins C, Agbaji O, Ugogwu P, et al. Assessment of liver fibrosis by transient elastography in patients with HIV and Hepatitis B virus coinfection in Nigeria. *Clin Infect Dis*. 2013;57(12):e189–e192.

45. Desalegn H, Aberra H, Berhe N, et al. Are non–invasive fibrosis markers for chronic hepatitis B reliable in sub–Saharan Africa? *Liver Int*. 2017;37(10):1461–1467.

46. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J Hepatol*. 2018;69(1):182–236.

47. McMahon BJ. The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. *Hepatol Int*. 2009;3:334–342.

48. Malagnino V, Salpini R, Maffongelli G, et al. High rates of chronic HBV genotype E infection in group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance. *PLoS One*. 2018;13(3):e0195045.

49. Miguel M, Núñez Ó, Traperó–Marugán M, et al. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice. *Ann Hepatol*. 2013;12(2):205–212.

50. Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. *Hepatology*. 2011;53(1):62–72.

51. Buti M, Fung S, Gane E, et al. Long–term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years. *Hepatol Int*. 2015;9(2):243–250.

52. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. *N Engl J Med*. 2004;351(15):1521–1531.

53. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5–year open–label follow–up study. *Lancet*. 2013;381(9865):468–475.

54. Howell J, Shimakawa Y, Nayagam S, et al. Prevention of hepatitis B–related liver fibrosis and liver cancer in Africa: The Prolifica Project. *Cancer Control*. 2015;97–102.

55. Buti M, Tsai N, Petersen J, et al. Seven–year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. *Dig Dis Sci*. 2015;60(5):1457–1464.

56. Papatheodoridis G, Vlachogiannakos I, Cholongitas E, et al. Discontinuation of oral antivirals in chronic hepatitis B: A systematic review. *Hepatology*. 2016;63(5):1481–1492.
57. Gallant J, Brunetta J, Crofoot G, et al. Brief report: Efficacy and safety of switching to a single-tablet regimen of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in hiv–1/hepatitis b–coinfected adults. J Acquir Immune Defic Syndr. 2016;73(3):294–298.

58. Huang YS, Chang SY, Sheng WH, et al. Virological response to tenofovir disoproxil fumarate in HIV–positive patients with lamivudine–resistant Hepatitis B virus coinfection in an area hyperendemic for Hepatitis B virus infection. PLoS One. 2016;11(12):e0169228.

59. Price H, Dunn D, Pillay D, et al. Suppression of HBV by tenofovir in HBV/HIV coinfected patients:A systematic review and meta–analysis. PLoS One. 2013;8(7):e68152.

60. Jamma S, Hussain G, Lau DT–Y. Current concepts of HBV/HCV coinfection:Coexistence, but not necessarily in harmony. Curr Hepat Rep. 2010;9(4):260–269.

61. Konstantinou D, Deutsch M. The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viral interactions and management. Ann Gastroenterol. 2015;28(2):221–228.

62. Calvaruso V, Craxi A. HBV recurrence after HCV clearance on DAAs: Sometimes they come back. J Hepatol. 2017;67(5):898–901.

63. Ageletopoulou I, Konstantakis C, Manolakopoulos S, et al. Risk of hepatitis B reactivation in patients treated with direct–acting antivirals for hepatitis C. World J Gastroenterol. 2017;23(24):4317–4323.

64. Triantos C, Kalafati M, Nikolopoulou V, et al. Meta–analysis:Antiviral treatment for hepatitis D. Aliment Pharmacol Ther. 2012;35(3):663–673.